These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11741599)

  • 61. CD95 ligand expression in dedifferentiated breast cancer.
    Müschen M; Moers C; Warskulat U; Niederacher D; Betz B; Even J; Lim A; Josien R; Beckmann MW; Häussinger D
    J Pathol; 1999 Nov; 189(3):378-86. PubMed ID: 10547600
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Novel Egr/NF-AT composite sites mediate activation of the CD95 (APO-1/Fas) ligand promoter in response to T cell stimulation.
    Li-Weber M; Laur O; Krammer PH
    Eur J Immunol; 1999 Sep; 29(9):3017-27. PubMed ID: 10508276
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia.
    Chu P; Deforce D; Pedersen IM; Kim Y; Kitada S; Reed JC; Kipps TJ
    Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3854-9. PubMed ID: 11891278
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression.
    Fulda S; Meyer E; Debatin KM
    Cancer Res; 2000 Jul; 60(14):3947-56. PubMed ID: 10919673
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Vitamin E inhibits CD95 ligand expression and protects T cells from activation-induced cell death.
    Li-Weber M; Weigand MA; Giaisi M; Süss D; Treiber MK; Baumann S; Ritsou E; Breitkreutz R; Krammer PH
    J Clin Invest; 2002 Sep; 110(5):681-90. PubMed ID: 12208869
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Up-regulation of c-FLIPshort and reduction of activation-induced cell death in CD28-costimulated human T cells.
    Kirchhoff S; Müller WW; Li-Weber M; Krammer PH
    Eur J Immunol; 2000 Oct; 30(10):2765-74. PubMed ID: 11069056
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Interferon alpha augments activation-induced T cell death by upregulation of Fas (CD95/APO-1) and Fas ligand expression.
    Kaser A; Nagata S; Tilg H
    Cytokine; 1999 Oct; 11(10):736-43. PubMed ID: 10525311
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The role of CD95 and CD95 ligand in cancer.
    Peter ME; Hadji A; Murmann AE; Brockway S; Putzbach W; Pattanayak A; Ceppi P
    Cell Death Differ; 2015 Apr; 22(4):549-59. PubMed ID: 25656654
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Regulation of CD95 ligand expression: a key element in immune regulation?
    Brunner T; Yoo NJ; Griffith TS; Ferguson TA; Green DR
    Behring Inst Mitt; 1996 Oct; (97):161-74. PubMed ID: 8950474
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pro- and anti-apoptotic CD95 signaling in T cells.
    Paulsen M; Janssen O
    Cell Commun Signal; 2011 Apr; 9():7. PubMed ID: 21477291
    [TBL] [Abstract][Full Text] [Related]  

  • 71. CD95-ligand (Fas-L)-expressing epidermal lymphocytes.
    De Panfilis G; Marcelli M; Pasolini G; Torresani C
    Br J Dermatol; 2000 Oct; 143(4):892-3. PubMed ID: 11069480
    [No Abstract]   [Full Text] [Related]  

  • 72. Intra- and Extracellular Effector Vesicles From Human T And NK Cells: Same-Same, but Different?
    Lettau M; Janssen O
    Front Immunol; 2021; 12():804895. PubMed ID: 35003134
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The Serine Protease CD26/DPP4 in Non-Transformed and Malignant T Cells.
    Chitadze G; Wehkamp U; Janssen O; Brüggemann M; Lettau M
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885056
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Molecular mechanisms of FasL-mediated 'reverse-signaling'.
    Malarkannan S
    Mol Immunol; 2020 Nov; 127():31-37. PubMed ID: 32905906
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Reverse Signaling of Tumor Necrosis Factor Superfamily Proteins in Macrophages and Microglia: Superfamily Portrait in the Neuroimmune Interface.
    Lee WH; Seo D; Lim SG; Suk K
    Front Immunol; 2019; 10():262. PubMed ID: 30838001
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Combined use of protein biomarkers and network analysis unveils deregulated regulatory circuits in Duchenne muscular dystrophy.
    Parolo S; Marchetti L; Lauria M; Misselbeck K; Scott-Boyer MP; Caberlotto L; Priami C
    PLoS One; 2018; 13(3):e0194225. PubMed ID: 29529088
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impairment of Fas-ligand-caveolin-1 interaction inhibits Fas-ligand translocation to rafts and Fas-ligand-induced cell death.
    Glukhova XA; Trizna JA; Proussakova OV; Gogvadze V; Beletsky IP
    Cell Death Dis; 2018 Jan; 9(2):73. PubMed ID: 29358576
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Induction of apoptosis in breast cancer cells in vitro by Fas ligand reverse signaling.
    Kolben T; Jeschke U; Reimer T; Karsten N; Schmoeckel E; Semmlinger A; Mahner S; Harbeck N; Kolben TM
    J Cancer Res Clin Oncol; 2018 Feb; 144(2):249-256. PubMed ID: 29185091
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Identification of SH3 domain proteins interacting with the cytoplasmic tail of the a disintegrin and metalloprotease 10 (ADAM10).
    Ebsen H; Lettau M; Kabelitz D; Janssen O
    PLoS One; 2014; 9(7):e102899. PubMed ID: 25036101
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Control of death receptor ligand activity by posttranslational modifications.
    Weinlich R; Brunner T; Amarante-Mendes GP
    Cell Mol Life Sci; 2010 May; 67(10):1631-42. PubMed ID: 20306114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.